Результат
Общий балл:
0
Риск инсульта:
0% в год
Рекомендация:
Низкий риск. Рассмотреть отказ от терапии или АСК.
Интерпретация баллов
Инструкции по медицинскому применению
Источники цитирования
- Cairns JA. ACP journal club. CHA2DS2-VASc had better discrimination than CHADS2 for predicting risk for thromboembolism in atrial fibrillation. Ann Intern Med. 2011 May 17;154(10):JC5-13. doi: 10.1059/0003-4819-154-10-201105170-02013. PubMed ID: 21576531
- Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011 Jan 31;342:d124. doi: 10.1136/bmj.d124. PubMed ID: 21282258
- January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Mar 28. pii: S0735-1097(14)01740-9. PubMed ID: 24685669
- Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010 Jun;123(6):484-8. Review. PubMed ID: 20569748
- Gage BF, Andrade A. ACP Journal Club. Various risk stratification schemes predict ischemic stroke and bleeding in atrial fibrillation. Ann Intern Med. 2012 Oct 16;157(8):JC4-13. doi: 10.7326/0003-4819-157-8-201210160-02013. PubMed ID: 23070515
- Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012 Jun;33(12):1500-10. doi: 10.1093/eurheartj/ehr488. Epub 2012 Jan 13. PubMed ID: 22246443